Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The uniQure N.V. (QURE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, uniQure files current reports on Form 8‑K, annual reports on Form 10‑K, and quarterly reports on Form 10‑Q that describe its gene therapy business, clinical programs, financial condition, and material agreements. These filings document the company’s work in hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
For uniQure, Form 8‑K filings are particularly important. They include clinical and regulatory updates on AMT‑130 for Huntington’s disease, such as topline Phase I/II data, details of pivotal trial design, and feedback from pre‑Biologics License Application meetings with the U.S. Food and Drug Administration. Other 8‑K reports describe public offerings of ordinary shares and pre‑funded warrants, amendments to senior secured term loan facilities with Hercules Capital, and the establishment of at‑the‑market equity programs. Filings also reference the company’s role in the multi‑year clinical development of a gene therapy for hemophilia B and its licensing arrangements with CSL.
On this page, investors can review uniQure’s SEC documents to understand how it reports results of operations, research and development spending, direct financial obligations, and other events that may affect QURE stock. Stock Titan enhances access to these filings with AI‑powered summaries that highlight key points from lengthy reports, helping readers quickly identify major clinical milestones, regulatory decisions, financing terms, and risk disclosures. Real‑time updates from EDGAR, along with structured access to items such as 8‑K current reports and other registered offerings, support deeper analysis of uniQure’s evolving gene therapy portfolio and capital structure.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an automatic open-market sale of 34,437 ordinary shares on March 2, 2026 at an average price of $9.95 per share. The filing explains the shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic instructions, so the sale was not a discretionary trade. After this transaction, Kapusta held 604,639 ordinary shares. The reported price reflects a weighted average from multiple trades between $9.67 and $10.25 per share.
uniQure N.V.’s Chief Financial Officer, Christian Klemt, reported an automatic tax-related share sale. On March 2, 2026, he sold 12,532 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under automatic sale instructions in the RSU agreement, meaning the sale was not a discretionary trade. Following the transaction, he directly owned 198,981 ordinary shares.
uniQure N.V.’s Chief Legal Officer, Jeannette Potts, reported an automatic sale of 8,578 ordinary shares. The shares were sold on March 2, 2026 in open-market transactions at a weighted average price of $9.95 per share.
According to the disclosure, the sale occurred upon the vesting of restricted share units and was made solely to cover estimated withholding taxes under automatic sale instructions, meaning it was not a discretionary trade by Potts. Following these transactions, she directly owned 106,495 ordinary shares of uniQure N.V.
uniQure N.V. Chief Medical Officer Walid Abi-Saab reported an automatic sale of 1,660 ordinary shares in an open-market transaction at a weighted average price of $9.95 per share. The shares were sold upon vesting of restricted share units solely to cover estimated withholding taxes under pre-set instructions, and were not a discretionary trade. After this transaction, Abi-Saab直接 owns 148,777 ordinary shares. The sale price reflected multiple trades between $9.67 and $10.25.
uniQure N.V. filed a Form 144 reporting a proposed sale of 34,437 ordinary shares. The filing lists Citigroup Global Markets as the broker and identifies 03/02/2026 as the filing date. The notice also discloses 49,999 restricted stock units vesting on 03/02/2026 as compensation. Separately, the filing records a sale by Matthew Kapusta of 12,378 ordinary shares on 02/25/2026 for $295,306.90.
uniQure N.V. filed a Form 144 reporting a proposed sale of 34,437 ordinary shares. The filing lists Citigroup Global Markets as the broker and identifies 03/02/2026 as the filing date. The notice also discloses 49,999 restricted stock units vesting on 03/02/2026 as compensation. Separately, the filing records a sale by Matthew Kapusta of 12,378 ordinary shares on 02/25/2026 for $295,306.90.
uniQure NV submitted a Form 144 notice relating to ordinary shares dated 03/02/2026. The filing lists 16,499 restricted stock units vesting on 03/02/2026 and records a sale of 6,217 ordinary shares by Klemt Christian on 02/25/2026
uniQure NV submitted a Form 144 notice relating to ordinary shares dated 03/02/2026. The filing lists 16,499 restricted stock units vesting on 03/02/2026 and records a sale of 6,217 ordinary shares by Klemt Christian on 02/25/2026
uniQure N.V. filed its Annual Report describing a broad gene therapy pipeline and major 2025–2026 developments. The lead Huntington’s disease program AMT‑130 showed favorable 36‑month high‑dose data and received FDA Breakthrough, RMAT, Orphan Drug and Fast Track designations.
However, after pre‑BLA and Type A meetings, the FDA said current Phase I/II data using external controls are unlikely to provide primary evidence for approval and strongly recommended a prospective, randomized, sham‑surgery‑controlled Phase III study. Early‑stage programs saw mixed outcomes, with promising AMT‑260 epilepsy data but safety‑driven pauses in the SOD1‑ALS trial (AMT‑162) and higher‑dose Fabry cohorts (AMT‑191).
To fund these efforts, uniQure completed two follow‑on equity offerings in 2025 raising net proceeds of about $404.2 million and entered a new $175.0 million term loan facility with Hercules, providing substantial capital but adding debt obligations through 2030.
uniQure N.V. filed its Annual Report describing a broad gene therapy pipeline and major 2025–2026 developments. The lead Huntington’s disease program AMT‑130 showed favorable 36‑month high‑dose data and received FDA Breakthrough, RMAT, Orphan Drug and Fast Track designations.
However, after pre‑BLA and Type A meetings, the FDA said current Phase I/II data using external controls are unlikely to provide primary evidence for approval and strongly recommended a prospective, randomized, sham‑surgery‑controlled Phase III study. Early‑stage programs saw mixed outcomes, with promising AMT‑260 epilepsy data but safety‑driven pauses in the SOD1‑ALS trial (AMT‑162) and higher‑dose Fabry cohorts (AMT‑191).
To fund these efforts, uniQure completed two follow‑on equity offerings in 2025 raising net proceeds of about $404.2 million and entered a new $175.0 million term loan facility with Hercules, providing substantial capital but adding debt obligations through 2030.
uniQure N.V. reported 2025 results and a key regulatory update on its Huntington’s disease program AMT-130. The company ended December 31, 2025 with $622.5 million in cash, cash equivalents and current investment securities, up from $367.5 million a year earlier, largely after raising about $404.2 million through public offerings of ordinary shares and pre-funded warrants.
Full-year 2025 revenue was $16.1 million, down from $27.1 million in 2024, mainly due to lower collaboration and contract manufacturing revenue, partly offset by higher license revenue. The net loss narrowed to $199.0 million, or $3.46 per share, compared with a $239.6 million loss, or $4.92 per share, in 2024. Shareholders’ equity improved to $198.9 million from a deficit of $6.8 million. Management expects the year-end cash position to fund operations into the second half of 2029.
On AMT-130, the U.S. FDA told uniQure that Phase I/II data using an external control are not sufficient as primary evidence of effectiveness to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. uniQure plans to seek a Type B FDA meeting in the second quarter of 2026 to discuss Phase III design. The company also highlighted progress in other gene therapy programs, including AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease, and completed enrollment of the first AMT-260 Phase I/IIa cohort.
uniQure N.V. reported 2025 results and a key regulatory update on its Huntington’s disease program AMT-130. The company ended December 31, 2025 with $622.5 million in cash, cash equivalents and current investment securities, up from $367.5 million a year earlier, largely after raising about $404.2 million through public offerings of ordinary shares and pre-funded warrants.
Full-year 2025 revenue was $16.1 million, down from $27.1 million in 2024, mainly due to lower collaboration and contract manufacturing revenue, partly offset by higher license revenue. The net loss narrowed to $199.0 million, or $3.46 per share, compared with a $239.6 million loss, or $4.92 per share, in 2024. Shareholders’ equity improved to $198.9 million from a deficit of $6.8 million. Management expects the year-end cash position to fund operations into the second half of 2029.
On AMT-130, the U.S. FDA told uniQure that Phase I/II data using an external control are not sufficient as primary evidence of effectiveness to support a marketing application and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study. uniQure plans to seek a Type B FDA meeting in the second quarter of 2026 to discuss Phase III design. The company also highlighted progress in other gene therapy programs, including AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease, and completed enrollment of the first AMT-260 Phase I/IIa cohort.
uniQure N.V. CEO and Managing Director Matthew C. Kapusta reported an open-market sale of 12,378 ordinary shares of the company at a weighted average price of $23.86 per share. The shares were sold automatically upon the vesting of restricted share units solely to cover estimated withholding taxes, under pre-set sale instructions, and not as a discretionary trade. After this transaction, Kapusta directly held 639,076 ordinary shares of uniQure.